drugset / Trial / NCT00822614

Safety of Fentanyl TAIFUN Treatment

NCT00822614

Phase 3 Unknown 500 enrolled Akela Pharma, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy

Timeline

Start
2008-12
Primary completion
2009-12
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified Inhaled
Comparator Hydromorphone Other / unclassified
Comparator Morphine Other / unclassified
Comparator Oxycodone Other / unclassified

Indications

No indication recorded.